A Phase 1 interventional study of LJM716 and BYL719 in Esophageal Squamous Cell Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States — 42 open to participants now, 50 under way, 3 of them phase 3. Esophageal Squamous Cell Carcinoma · United States.
Among the 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States, this one is the 72nd largest by enrollment of the 120 interventional ones that give a count, is one of 3 that started in 2013, is one of 44 in phase 1, and was the 56th registered.
678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →42 of the 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States are open now. Recruiting first, the newest first:
Crescent Biopharma, Inc. · Sites in United States
Ages 18+
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States, Japan
Ages 18+
InduPro, Inc. · Sites in United States
Ages 18+
BeOne Medicines · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 61 · Phase 2 68 · Phase 3 12
First in 1992; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 64 across 564 interventional studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 61 across the 120 interventional studies, 360 across the 6 observational. Of the 85 that completed or were terminated, 29 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 138 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 6 studies filed under Esophageal Squamous Cell Carcinoma — fewer than ten, so there is no comparison to draw.
13 of the studies in Esophageal Squamous Cell Carcinoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04550260Phase 3AstraZenecaStudy of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC | 2027-06-30 |
| NCT06545331ExelixisStudy of XB010 in Subjects With Solid Tumors | 2026-11-23 |
| NCT04510129Cofactor Genomics, Inc.A Multicenter Cancer Biospecimen Collection Study | 2027-02 |
| NCT06047379Neonc Technologies, Inc.Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | 2027-02-28 |
| NCT04221893University of California, San FranciscoRadiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers | 2027-04-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 138 studies in Esophageal Squamous Cell Carcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To study the safety and efficacy of the combination of LJM716 and BYL719 against currently available treatments of physician's choice in previously treated esophageal squamous cell carcinoma patients.
The study design included a Phase 1b dose escalation portion to define the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) for the combination of LJM716 and alpelisib, followed by an open-label, randomized Phase 2 part to compare anti-tumor activity of LJM716-alpelisib combination versus physician's choice of second-line therapy (paclitaxel, docetaxel, irinotecan). However, the phase 2 part was not conducted as the study was terminated early due to limited anti-tumor activity with LJM716-alpelisib combination observed in phase 1b.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the LJM716-BYL719 combination arm to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
Drug: LJM716 · Drug: BYL719
approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the Paclitaxel, Docetaxel or Irinotecan arm (physician's choice arm) to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the LJM716-BYL719 combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
Drug: Paclitaxel · Drug: Docetaxel · Drug: Irinotecan
LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label
Phase Ib primary outcome measure: Incidence rate of dose limiting toxicities (DLTs).
The open-label dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose(s) and/or Recommended Phase II Dose (s) guided by the safety (incidence of dose limiting toxicities), efficacy, pharmacokinetics and pharmacodynamics data.
Time frame: approximately 8 months
Phase II primary outcome measure: Progression free survival (PFS)
Progression-free survival is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate assessment.
Time frame: Every 6 weeks from the date of the baseline computed-tomography (CT) scan until the date of first documented evidence of disease progression or date of death, whichever comes first, assessed up to 24 months.
Safety and tolerability of the LJM716-BYL719
This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, reductions and dose intensity.
Time frame: Every 21 days from the date of the baseline visit until the end of study visit (about 5 months)
Best overall response (BOR), per RECIST 1.1 (Ph 1b )
BOR will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.
Time frame: Every 21 days from the date of baseline computed tomography (CT) scan until end of treatment visit (about 4 months)
Plasma concentration versus time profiles Plasma PK parameters of LJM716, BYL719
Plasma concentration versus time profiles Plasma PK parameters will be used to characterize the PK profiles of LJM716 and BYL719 when used in combination
Time frame: Baseline, 2hr,4hr,8hr,24hr,48hr,96hr, 168 hr, every 21 days for 10 cycles (21 days each) and at end of treatment (about 4 months)
Overall response rate (ORR) per RECIST 1.1 (Ph 1b )
Overall response rate will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.
Time frame: Every 21 days from the date of the baseline computed tomography (CT) scan until the end of treatment visit (about 4 months)
Duration of response (DOR) per RECIST 1.1 (Ph 1b )
Duration of response will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.
Time frame: Every 21 days from the date of the baseline computed tomography (CT) scan until the end of treatment visit (about 4 months)
Disease control rate (DCR) per RECIST 1.1 (Ph 1b )
Disease control rate will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.
Time frame: Every 21 days from the date of the baseline computed tomography (CT) scan until the end of treatment visit (about 4 months)
Overall survival (OS) per RECIST 1.1 (for Ph 1b )
Overall survival will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.
Time frame: Every 21 days from the date of the baseline computed tomography (CT) scan until the end of treatment visit (about 4 months)
Progression free survival (PFS) per RECIST 1.1 (Ph 1b )
Progression free survival will be used to further assess the anti-tumor activity of LJM716-BYL719 combination versus Paclitaxel, Docetaxel or Irinotecan.
Time frame: Every 21 days from the date of the baseline computed tomography (CT) scan until the end of study visit (about 5 months)
Plan to share: No
Ran from Jul 2013 to primary completion in Jun 2016, 34 months.
Of 42 phase 1 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 68. This study's 34 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elgemtumab · Alpelisib
Esophageal Squamous Cell Carcinoma →